Quantification of Trace Polymorphic Impurity in Celecoxib with Powder X-Ray Diffraction Technique
Journal of Pharmaceutical and BioTech Industry · 2025
DOI: 10.3390/jpbi2020004 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pharmaceutical and BioTech Industry, 2025. Verfasst von Amita G. Dhadphale und 1 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
A selective inhibitor of cyclooxygenase-2 (COX-2), Celecoxib (CEB), known for its anti-inflammatory properties, can exhibit polymorphism, with Form III often emerging as an undesired crystalline impurity during the green manufacturing process of the preferred Form I. Controlling the Form III content in the drug product is crucial, as different crystalline forms can impact drug bioavailability and therapeutic efficacy. This study presents a method to quantify the weight percentage of Form III in the bulk of CEB Form I by employing powder X-ray diffraction (PXRD). Initially, pure Form I and III of CEB were characterized using DSC, FTIR, and PXRD, supporting the method’s development. Binary mixtures, with varying ratios of CEB polymorphs Form I and Form III, were prepared and analyzed using continuous scans over an angular (2θ) range of 2–40. The calibration curve was constructed using 2θ unique peaks for Form I and Form III, respectively. Linear regression analysis exhibited a strong linear relationship within the weight ratio range of 1–20%. The developed method was validated to assess recovery, precision, ruggedness, limits of detection, and quantitation. These findings indicate that the method exhibits repeatability, sensitivity, and accuracy. The newly developed and validated PXRD method is applicable for quality control of CEB Form I produced through the green melt crystallization process by detecting low levels of Form III polymorphic impurity. This research significantly contributes to ensuring the clinical efficacy and manufacturing quality of Celecoxib by providing a reliable method for controlling polymorphic impurities.
Zitieren
APA
Dhadphale, A. G., & Donde, K. J. (2025). Quantification of Trace Polymorphic Impurity in Celecoxib with Powder X-Ray Diffraction Technique. Journal of Pharmaceutical and BioTech Industry. https://doi.org/10.3390/jpbi2020004
Vancouver
Dhadphale AG, Donde KJ. Quantification of Trace Polymorphic Impurity in Celecoxib with Powder X-Ray Diffraction Technique. Journal of Pharmaceutical and BioTech Industry. 2025. doi:10.3390/jpbi2020004
BibTeX
@article{Dhadphale2025,
author = {Dhadphale, Amita G. and Donde, Kamini J.},
title = {Quantification of Trace Polymorphic Impurity in Celecoxib with Powder X-Ray Diffraction Technique},
journal = {Journal of Pharmaceutical and BioTech Industry},
year = {2025},
doi = {10.3390/jpbi2020004}
}
EUVIMED